{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/08/04/3338014/0/en/Nurix-Therapeutics-Announces-First-Patient-Enrolled-in-Registrational-Phase-3-DAYBreak-CLL-306-Trial-of-Bexobrutideg-in-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-Small-Lymph.html", "message": "News view counter 865314 successfully enlarged"}